Rankings
▼
Calendar
LGND Q1 2018 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q1 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$56M
+91.9% YoY
Gross Profit
$55M
98.6% margin
Operating Income
$37M
66.0% margin
Net Income
$45M
80.6% margin
EPS (Diluted)
$1.83
QoQ Revenue Growth
+11.3%
Cash Flow
Operating Cash Flow
$61M
Free Cash Flow
$60M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$755M
Total Liabilities
$257M
Stockholders' Equity
$497M
Cash & Equivalents
$51M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$56M
$29M
+91.9%
Gross Profit
$55M
$29M
+91.4%
Operating Income
$37M
$10M
+262.6%
Net Income
$45M
$5M
+791.5%
Revenue Segments
License Fees, Milestones, and Product, Other
$31M
29%
License Fees
$27M
25%
Royalty
$21M
19%
Royalty, Promacta
$16M
14%
Material Sales, Captisol
$4M
4%
Royalty, Kyprolis
$3M
3%
Milestone
$3M
3%
Royalty, Evomela
$2M
1%
License Fees, Milestones, and Product, Other, Product, Other
$1M
1%
Royalty, Product, Other
$400,000
0%
← FY 2018
All Quarters
Q2 2018 →